文献速递眼底病与葡萄膜炎

急性视网膜坏死:定量聚合酶链反应病毒学特征、治疗管理与临床结局

Acute Retinal Necrosis: Virological Features Using Quantitative Polymerase Chain Reaction, Therapeutic Management, and Clinical Outcomes.
PubMed 文献 · Am J Ophthalmol · 2019-08-23

该回顾性观察性病例系列纳入法国里昂两个眼科部门的24例(25眼)急性视网膜坏死患者,评估强化玻璃体腔注射治疗下的qPCR病毒载量变化、注射次数、视网膜脱离率和视力结局。结论认为多次且长期的玻璃体腔注射作为辅助治疗可能改善预后,qPCR可监测治疗反应并通过初始平台期延长提示抗病毒耐药。

要点

  • 最终视力≤20/200者占20%,视网膜脱离率为16%。
  • 病毒载量动力学呈三相:初始平台期、对数下降期和转阴期。
  • 病毒载量对数平均衰减为每日0.076,平均转阴时间为56.1天。

核心结论

  • 多次且长期的玻璃体腔注射作为辅助治疗,可能通过降低视网膜脱离风险和改善视力来改善接受治疗患者的预后。
  • qPCR能够监测治疗反应,并可通过检测病毒载量初始平台期延长的病例来提供抗病毒治疗耐药的证据。

研究设计与样本

  • 回顾性观察性病例系列,纳入法国里昂两个眼科部门接受治疗并随访的24例(25眼)急性视网膜坏死患者。
  • 评估结局包括治疗期间qPCR病毒载量特征、抗病毒玻璃体腔注射次数、视网膜脱离率和最佳矫正视力。

主要发现

  • 最终视力≤20/200者占20%,视网膜脱离率为16%。
  • 病毒载量动力学呈三相变化:初始平台期(不一致)、对数下降期和转阴期。
  • 病毒载量对数平均衰减估算为每日0.076,平均转阴时间为56.1天。
  • 玻璃体腔注射次数中位数为9次(范围0-28次)。
  • 10例患者接受注射治疗直至病毒载量不可检测;1例病毒载量初始平台期延长的患者观察到阿昔洛韦耐药。

临床怎么用

  • 作者认为,多次且长期的玻璃体腔注射作为辅助治疗可能改善预后。
  • 作者认为,qPCR可监测治疗反应,并通过检测病毒载量初始平台期延长的病例提供抗病毒耐药证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate outcomes of patients treated with intensive intravitreal therapy and to describe the evolution of quantitative real-time polymerase chain reaction (qPCR) in patients treated for acute retinal necrosis (ARN) syndrome. DESIGN: Retrospective observational case series. METHODS: This study included 25 eyes of 24 patients with ARN who were treated and followed up in 2 departments of ophthalmology in Lyon, France. Assessed outcomes included qPCR viral load profile during treatment, number of antiviral intravitreal injections (IVT), retinal detachment rate, and best-corrected visual acuity. RESULTS: Final visual acuity was 20/200 or less in 20% of cases; the rate of retinal detachment was 16%. Viral load kinetics changed in 3 phases: a first plateau period that was not consistent, a logarithmic decrease phase, and a negativation phase. Mean decay of the logarithm of the viral load was estimated at 0.076 per day; mean time of negativation was 56.1 days. Median IVT number was 9 (range, 0-28). Ten patients were treated with injections until the viral load was undetectable. Resistance to acyclovir was observed in a patient with a prolonged initial plateau of the viral load. CONCLUSIONS: Numerous and prolonged IVTs, used as adjunctive therapy, could improve the prognosis of treated patients by decreasing the risk of retinal detachment and improving visual acuity. QPCR enables monitoring of the response to treatment and can provide evidence for resistance to antiviral treatment by enabling the detection of cases with a prolonged initial plateau of viral load.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hafidi M, Janin-Manificat H, Denis P, et al. Acute Retinal Necrosis: Virological Features Using Quantitative Polymerase Chain Reaction, Therapeutic Management, and Clinical Outcomes. Am J Ophthalmol. 2019. PMID: 31449790. doi:10.1016/j.ajo.2019.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。